Life Lessons Learned on the Journey to Marriage, Motherhood, Entrepreneurship, Divorce, Surviving Breast Cancer and Finding New Love

Delphyne Lomax Taylor
V&L Research and Consulting, Inc.

The Lomax Group, Inc.

The Networthing Group
Founding Partner

About Delphyne

Delphyne Lomax Taylor was diagnosed with Breast Cancer in October 2013.  She had a right mastectomy; chemo and radiation in 2014.  After two years of additional surgeries, she looks forward to celebrating seven years of being Cancer Free in November 2020.  Most recently she has published her book, Woman 2 Woman Life Lessons Learned on the Journey to Marriage, Motherhood, Entrepreneurship, Divorce, Surviving Breast Cancer and Finding New Love. More info

Appearances and Events

Virtual Book Release Announcement

Interviews & Videos

About The Book

This book was inspired by my life experiences and those of countless women of all ages, races, and socioeconomic backgrounds. We all are susceptible to various forms of cancer. We all desire opportunities to grow personally and professionally. And, we all need a loving circle of support.

This book, then, seeks to engage readers in a conversation about such pertinent topics as: marriage;being a mother; divorce; finding new love; discovering one’s life purpose; entrepreneurship; and, because I am a breast cancer survivor, increasing awareness of the importance of getting a yearly mammogram. This is essential because early detection is one of the key factors in surviving breast cancer.The additional inspiration for writing this book was turning 60. For months leading up to my 60th birthday,I could feel an internal psychological and emotional shift taking place. Although I now am 62, over the last few years, I could feel myself coming to peace with the full realization and acceptance, that without my various life experiences, I would not be the person I am today. By no means am I suggesting that I am perfect. Rather, it is celebrating the fact that I no longer feel the self-imposed pressure to try to be perfect. I now am at a place in my life where I truly am at peace with myself, at peace with all of who I am. And, I am fully aware that this is a blessing, a gift in and of itself.




For more information about breast cancer, you can also visit the website of the Susan G. Komen Breast Cancer Foundation:

Figure 3.1 (below) shows the breast cancer screening recommendations for women at average risk from 3 major health organizations.

Learn about screening recommendations for women at higher than average risk of breast cancer. is a  nonprofit organization dedicated to informing and empowering individuals to protect their breast health and overcome the challenges of breast cancer.  


Triple-Negative Breast Cancer

Triple-negative breast cancer is cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein.These results mean the growth of the cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. So, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2 protein receptors. Still, other medicines are used to successfully treat triple-negative breast cancer. About 10-20% of breast cancers are triple-negative breast cancers. For doctors and researchers, there is intense interest in finding new medications that can treat this kind of breast cancer. Studies are trying to find out whether certain medications can interfere with the processes that cause triple-negative breast cancer to grow.  


Three common features of triple-negative breast cancer

    • Triple-negative breast cancer is considered to be more aggressive and have a poorer prognosis than other types of breast cancer, mainly because there are fewer targeted medicines that treat triple-negative breast cancer. Studies have shown that triple-negative breast cancer is more likely to spread beyond the breast and more likely to recur (come back) after treatment.
    • It tends to be higher grade than other types of breast cancer. The higher the grade, the less the cancer cells resemble normal, healthy breast cells in their appearance and growth patterns. On a scale of 1 to 3, triple-negative breast cancer often is grade 3.It usually is a cell type called “basal-like.” “Basal-like” means that the cells resemble the basal cells that line the breast ducts. Basal-like cancers tend to be more aggressive, higher grade cancers — just like triple-negative breast cancers. Most but not all basal-like breast cancers are triple negative, and most but not all triple-negative breast cancers are basal-like.

Who gets triple-negative breast cancer?

Anyone can be diagnosed with triple-negative breast cancer. Still,researchers have found that it is more common in:

    • Younger people. Triple-negative breast cancer is more likely to be diagnosed in people younger than age 50. Other types of breast cancer are more commonly diagnosed in people age 60 or older.
    • African-American and Hispanic women. Triple-negative breast cancer is more likely to be diagnosed in African-American women and Hispanic women. Asian women and non-Hispanic white women are less likely to be diagnosed with this type of cancer.
    • People with a BRCA1 mutation. About 70% of breast cancers diagnosed in people with an inherited BRCA mutation, particularly BRCA1, are triple-negative





NOTE: The statistics and references to research on breast cancer, listed above and throughout the book, were recorded on October 5, 2020 when this book was first published. Given the constant advances in research and treatment of cancer, new and more recent research and statistics will continually become available after the publication of this book.